Protocol Ledger

NCT04973228 · Phase III · COMPLETED

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Interventional Phase III clinical trial protocol NCT04973228 sponsored by Arcutis Biotherapeutics in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-08 Enrollment: 457 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04973228
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)457 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04973228
Protocol FieldVerified Registry Value
NCT IdentifierNCT04973228
Consolidated Lead SponsorArcutis Biotherapeutics
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment457 participants (ACTUAL)
Registered Start Date2021-07-08
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI